Compare AXL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXL | CTMX |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.5M | 596.2M |
| IPO Year | 1999 | 2015 |
| Metric | AXL | CTMX |
|---|---|---|
| Price | $6.34 | $4.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $6.93 | $6.50 |
| AVG Volume (30 Days) | 2.9M | ★ 3.1M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.55 | ★ 50.22 |
| EPS | ★ 0.34 | 0.24 |
| Revenue | ★ $5,833,600,000.00 | $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.67 | ★ $17.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $0.40 |
| 52 Week High | $7.03 | $4.62 |
| Indicator | AXL | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 55.42 |
| Support Level | $6.40 | $3.66 |
| Resistance Level | $6.65 | $4.33 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 62.94 | 72.38 |
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.